...)as the key triggering agent in AD, making it the ideal target for disease-modifying therapies. Preclinical studies provided extensive support for passive Aβ42 immunotherapy, leading to human clinical trials with different antibodies. Objective: Examine the status of clinical trials for passive immunotherapy...

.... Motor neuron diseases Amyotrophic lateral sclerosis Biomarker Immunotherapy Neuroinflammation The study group included 11 patients with slow-progression MND; the control group included 9 patients with typical MND. Globally, 5 patients had VGKC-complex Abs >100 p M : 4 in the study...

... and activated microglia. Several immunotherapies against Aβ have been shown to reduce amyloid neuropathology. However, the role of the associated glia in the recovery process requires clarification. Previously, we described the safety and effectiveness in aged domestic canine with cognitive dysfunction syndrome...

...Einar M. Sigurdsson Disappointing findings from recent phase III trials on amyloid-β (Aβ) immunotherapy for Alzheimer's disease (AD) have shifted the focus of such treatments to the tau protein. As tau pathology correlates better with the degree of dementia than Aβ plaque burden, it is a more...

... in both the prevention and therapeutic studies. Insoluble Aβ levels in hemibrain homogenates were not significantly different between immunized and control mice. Microhemorrhage was not observed with anti-pE3-Aβ immunotherapy. Conclusions: Selective removal of pE3-Aβ lowered general Aβ plaque deposition...

..., especially Aβ plaque pathology. The ability to monitor in vivo retinal plaque dynamics in response to immunotherapy is also assessed. Methods: Literature analysis of retinal AD pathology and imaging is provided. In our studies, systemic curcumin is administered to enable monitoring of retinal Aβ plaques...

..., instructions or products referred to in the content or advertisements. Alzheimer’s disease β-Amyloid protein Experimental therapies Immunotherapy Neuroinflammation T-cells Diseases Inflammation Neurodegenerative Dis 2008;5:194 196 DOI: 10.1159/000113700 Published online: March 6, 2008 Progress...

... Dora Gamesa aElan Pharmaceuticals, Inc., South San Francisco, Calif., bWyeth, Wyeth Research, Cambridge, Mass., and cDiscovery Neuroscience, Wyeth Research, Princeton, N.J., USA Key Words Immunotherapy Alzheimer s disease Amyloid- Abstract Background: In vivo administration of antibodies against...

... to in the content or advertisements. Immunotherapy Aβ immunization Alzheimer’s disease B cells T cells Diseases Special Topic Section: Immunotherapies and Related Strategies in Alzheimer s Disease Editor: Dale B. Schenk (San Francisco, Calif.) Commentary Neurodegenerative Dis 2005;2:267 272 DOI...

... of immunotherapy for Alzheimer’s disease might be developed. 25 11 2004 4 01 2005 10 8 2005 Diseases Original Paper Neurodegenerative Dis 2005;2:36 43 DOI: 10.1159/000086429 Received: November 25, 2004 Accepted after revision: January 4, 2005 Passive Immunization of the A 42(43) C-Terminal...